Literature DB >> 29210635

Potential Drug Targets in the Pentose Phosphate Pathway of Trypanosomatids.

Inês Loureiro1,2, Joana Faria1,2, Nuno Santarem1,2, Terry K Smith3, Joana Tavares1,2, Anabela Cordeiro-da-Silva1,2,4.   

Abstract

The trypanosomatids, Trypanosoma brucei, Trypanosoma cruzi and Leishmania spp, are causative agents of important human diseases such as African sleeping sickness, Chagas' disease and Leishmaniasis, respectively. The high impact of these diseases on human health and economy worldwide, the unsatisfactory available chemotherapeutic options and the absence of human effective vaccines, strongly justifies the search for new drugs. The pentose phosphate pathway has been proposed to be a viable strategy to defeat several infectious diseases, including those from trypanosomatids, as it includes an oxidative branch, important in the maintenance of cell redox homeostasis, and a non-oxidative branch in which ribose 5-phosphate and erythrose 4-phosphate, precursors of nucleic acids and aromatic amino acids, are produced. This review provides an overview of the available chemotherapeutic options against these diseases and discusses the potential of genetically validated enzymes from the pentose phosphate pathway of trypanosomatids to be explored as potential drug targets. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Trypanosomatids; drug targets; pentose phosphate pathway; treatment.

Mesh:

Substances:

Year:  2018        PMID: 29210635     DOI: 10.2174/0929867325666171206094752

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  5 in total

1.  Metabolomics analysis of a mouse model for chronic exposure to ambient PM2.5.

Authors:  Yanyi Xu; Wanjun Wang; Ji Zhou; Minjie Chen; Xingke Huang; Yaning Zhu; Xiaoyun Xie; Weihua Li; Yuhao Zhang; Haidong Kan; Zhekang Ying
Journal:  Environ Pollut       Date:  2019-02-01       Impact factor: 8.071

Review 2.  Engineering ribose-5-phosphate isomerase B from a central carbon metabolic enzyme to a promising sugar biocatalyst.

Authors:  Hengtao Tang; Xin Ju; Jing Zhao; Liangzhi Li
Journal:  Appl Microbiol Biotechnol       Date:  2021-01-04       Impact factor: 4.813

3.  Toward Chemical Validation of Leishmania infantum Ribose 5-Phosphate Isomerase as a Drug Target.

Authors:  Emily A Dickie; Céline Ronin; Mónica Sá; Fabrice Ciesielski; Nathalie Trouche; Joana Tavares; Nuno Santarem; Louise L Major; Iain K Pemberton; Jane MacDougall; Terry K Smith; Anabela Cordeiro-da-Silva; Paola Ciapetti
Journal:  Antimicrob Agents Chemother       Date:  2021-06-17       Impact factor: 5.191

4.  Biophysical and Structural Characterization of Ribulose-5-phosphate Epimerase from Leishmania donovani.

Authors:  Bandigi Narsimulu; Rahila Qureshi; Pranay Jakkula; Sayanna Are; Insaf Ahmed Qureshi
Journal:  ACS Omega       Date:  2021-12-17

5.  Murine infection with bioluminescent Leishmania infantum axenic amastigotes applied to drug discovery.

Authors:  David Mendes Costa; Pedro Cecílio; Nuno Santarém; Anabela Cordeiro-da-Silva; Joana Tavares
Journal:  Sci Rep       Date:  2019-12-12       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.